Abstract
Pirfenidone (PFD) is an anti-fibrotic drug used to treat idiopathic pulmonary fibrosis by inducing G1 cell cycle arrest in fibroblasts. We hypothesize that PFD can induce G1 cell cycle arrest in different types of cells, including cancer cells. To investigate the effects of PFD treatment on the growth of human prostate cancer (PCa) cells, we used an androgen-sensitive human PCa cell line (LNCaP) and its sublines (androgen-low-sensitive E9 and F10 cells and androgen-insensitive AIDL cells), as well as an androgen-insensitive human PCa cell line (PC-3). PFD treatment suppressed the growth of all PCa cells. Transforming growth factor β1 secretion was significantly increased in PFD-treated PCa cells. In both LNCaP and PC-3 cells, PFD treatment increased the population of cells in the G0/G1 phase, which was accompanied by a decrease in the S/G2 cell population. CDK2 protein expression was clearly decreased in PFD-treated LNCaP and PC-3 cells, whereas p21 protein expression was increased in only PFD-treated LNCaP cells. In conclusion, PFD may serve as a novel therapeutic drug that induces G1 cell cycle arrest in human PCa cells independently of androgen sensitivity. Thus, in the tumor microenvironment, PFD might target not only fibroblasts, but also heterogeneous PCa cells of varying androgen-sensitivity levels.
Highlights
The number of males diagnosed with prostate cancer (PCa) is increasing worldwide [1]
Cell line and its sublines to investigate the effects of PFD treatment on the growth of human PCa cells, focusing on androgen sensitivity
The androgen-sensitive, androgen receptor (AR)-positive human PCa cell line LNCaP, and the androgen-insensitive, AR-negative human PCa cell line PC-3 were obtained from the American Type Culture Collection (Manassas, VA, USA)
Summary
Kenichiro Ishii 1,2, * , Takeshi Sasaki 1 , Kazuhiro Iguchi 3 , Manabu Kato 1 , Hideki Kanda 1 , Yoshifumi Hirokawa 2 , Kiminobu Arima 1 , Masatoshi Watanabe 2 and Yoshiki Sugimura 1. Received: 11 December 2018; Accepted: 28 December 2018; Published: 4 January 2019
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.